Phase 2b Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
Phase 2b, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to
evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects 16 years
of age or older, with HO